LU91163I2 - Hydrobromure de darifénacine et ses dérivés pharmaceutiquement acceptables (EMSELEX. - Google Patents

Hydrobromure de darifénacine et ses dérivés pharmaceutiquement acceptables (EMSELEX.

Info

Publication number
LU91163I2
LU91163I2 LU91163C LU91163C LU91163I2 LU 91163 I2 LU91163 I2 LU 91163I2 LU 91163 C LU91163 C LU 91163C LU 91163 C LU91163 C LU 91163C LU 91163 I2 LU91163 I2 LU 91163I2
Authority
LU
Luxembourg
Prior art keywords
emselex
pharmaceutically acceptable
acceptable derivatives
darifenacin hydrobromide
darifenacin
Prior art date
Application number
LU91163C
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10780813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91163(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LU91163I2 publication Critical patent/LU91163I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
LU91163C 1995-09-15 2005-04-19 Hydrobromure de darifénacine et ses dérivés pharmaceutiquement acceptables (EMSELEX. LU91163I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9518953.6A GB9518953D0 (en) 1995-09-15 1995-09-15 Pharmaceutical formulations
PCT/EP1996/003719 WO1997009980A1 (fr) 1995-09-15 1996-08-21 Formulations pharmaceutiques contenant de la darifenacine

Publications (1)

Publication Number Publication Date
LU91163I2 true LU91163I2 (fr) 2005-06-20

Family

ID=10780813

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91163C LU91163I2 (fr) 1995-09-15 2005-04-19 Hydrobromure de darifénacine et ses dérivés pharmaceutiquement acceptables (EMSELEX.

Country Status (32)

Country Link
US (1) US6106864A (fr)
EP (2) EP0850059B1 (fr)
JP (1) JP3403203B2 (fr)
KR (1) KR100348585B1 (fr)
CN (1) CN1303998C (fr)
AR (1) AR005231A1 (fr)
AT (2) ATE233090T1 (fr)
BR (2) BR9610153A (fr)
CA (1) CA2230314C (fr)
CO (1) CO4750822A1 (fr)
CY (3) CY2468B1 (fr)
CZ (1) CZ294024B6 (fr)
DE (4) DE122005000024I2 (fr)
DK (2) DK0850059T3 (fr)
EG (1) EG23826A (fr)
ES (2) ES2188782T3 (fr)
FR (1) FR05C0019I2 (fr)
GB (1) GB9518953D0 (fr)
HU (2) HU227397B1 (fr)
IL (1) IL122746A (fr)
LU (1) LU91163I2 (fr)
MY (1) MY125662A (fr)
NL (1) NL300190I2 (fr)
NO (2) NO314783B1 (fr)
NZ (1) NZ316924A (fr)
PL (1) PL185604B1 (fr)
PT (1) PT1245231E (fr)
RU (1) RU2163803C2 (fr)
TR (1) TR199800461T1 (fr)
TW (1) TW442300B (fr)
WO (1) WO1997009980A1 (fr)
ZA (1) ZA967745B (fr)

Families Citing this family (292)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010029519A (ko) * 1996-09-19 2001-04-06 이곤 이 버그 요실금 치료 방법
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US7858119B1 (en) * 2000-05-09 2010-12-28 Amina Odidi Extended release pharmaceuticals
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
GB0129962D0 (en) * 2001-12-14 2002-02-06 Pfizer Ltd Method of treatment
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
CA2451267A1 (fr) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Utilisations pharmaceutiques de ligands alpha2delta
RU2331438C2 (ru) 2002-12-13 2008-08-20 Уорнер-Ламберт Компани Ллс Альфа-2-дельта лиганд для лечения симптомов нижних мочевыводящих путей
US20040235857A1 (en) * 2003-02-11 2004-11-25 Pfizer Inc Crystalline therapeutic agent
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20040186046A1 (en) * 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
US7268147B2 (en) * 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
WO2004112756A1 (fr) 2003-06-26 2004-12-29 Isa Odidi Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
US20050043300A1 (en) * 2003-08-14 2005-02-24 Pfizer Inc. Piperazine derivatives
AU2004268840B9 (en) * 2003-09-03 2011-02-03 Pfizer Inc. Benzimidazolone compounds having 5-HT4 receptor agonistic activity
EP1663398B1 (fr) 2003-09-12 2009-11-25 Pfizer Limited Associations comprenant des ligands alpha-2-delta et des inhibiteurs du recaptage de la serotonine et de la noradrenaline
SI1682545T1 (sl) * 2003-10-03 2008-04-30 Pfizer Derivati tropana, substituirani z imidazopiridinom, z antagonisticno aktivnostjo receptorja CCR5 zazdravljenje HIV in vnetja
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
GB0402491D0 (en) * 2004-02-04 2004-03-10 Pfizer Ltd Medicaments
US7629358B2 (en) * 2004-03-17 2009-12-08 Pfizer Inc Compounds useful for the treatment of diseases
AU2005223483B2 (en) * 2004-03-18 2009-04-23 Zoetis Llc N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
US20050215542A1 (en) * 2004-03-23 2005-09-29 Pfizer Inc Compounds for the treatment of diseases
BRPI0507877A (pt) * 2004-03-23 2007-07-24 Pfizer derivados de formamida, composição farmacêutica, uso dos mesmos e combinação
US7538141B2 (en) * 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
US7569572B2 (en) * 2004-04-07 2009-08-04 Pfizer Inc Pyrazolo[4,3-D]pyrimidines
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
EA200801608A1 (ru) * 2004-06-15 2008-10-30 Пфайзер Инк. Производные бензимидазолонкарбоновой кислоты
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
PL1778686T3 (pl) 2004-08-12 2009-04-30 Pfizer Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
AU2005276132B2 (en) * 2004-08-26 2011-09-29 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
RS51362B (en) 2004-08-26 2011-02-28 Pfizer Inc. ENANTIOMERALLY PURE AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS
JP2008518905A (ja) * 2004-11-02 2008-06-05 ファイザー株式会社 スルホニルベンゾイミダゾール誘導体
US20060111416A1 (en) * 2004-11-24 2006-05-25 Lane Charlotte A L Octahydropyrrolo[3,4-C]pyrrole derivatives
AP2007004157A0 (en) 2005-03-17 2007-10-31 Pfizer N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain
US20110152326A1 (en) * 2005-03-28 2011-06-23 Takeshi Hanazawa Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists
US20080146643A1 (en) * 2005-06-15 2008-06-19 Pfizer Limited Combination
BRPI0611798A2 (pt) * 2005-06-15 2009-01-13 Pfizer Ltd compostos de arilpirazàis substituÍdos, sua composiÇço farmacÊutica e uso
US20070149464A1 (en) * 2005-06-15 2007-06-28 Pfizer Inc. Combination
US20080176865A1 (en) * 2005-06-15 2008-07-24 Pfizer Limited Substituted arylpyrazoles
US7645786B2 (en) * 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
EP1912968A1 (fr) * 2005-08-04 2008-04-23 Pfizer Limited Composes piperidinoyl-pyrrolidine et piperidinoyl-piperidine
CA2618103A1 (fr) * 2005-08-10 2007-02-15 Pfizer Limited Derives de triazole substitues en tant qu'antagonistes d'oxytocine
ZA200802811B (en) 2005-09-02 2009-09-30 Theravida Inc Therapy for the treatment of disease
CA2547216A1 (fr) 2005-09-21 2007-03-21 Renuka D. Reddy Procede de recuit de l'atorvastatine amorphe
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007109142A2 (fr) * 2006-03-17 2007-09-27 Oregon Health & Science University Antagonistes du recepteur muscarinique m3 pour le traitement des tumeurs exprimant le recepteur muscarinique m3
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
EP2021338A1 (fr) 2006-05-09 2009-02-11 Pfizer Products Inc. Dérivés d'acide cycloalkylaminé et compositions pharmaceutiques à base de ceux-ci
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20100256357A1 (en) * 2006-08-09 2010-10-07 Agouron Pharmaceuticals, Inc. Heterocycles useful as inhibitors of carbonic anhydrase
CA2664251A1 (fr) * 2006-09-12 2008-03-20 Cephalin Pharmaceuticals Inc. Traitement de la douleur par l'isovaline
WO2008035195A1 (fr) * 2006-09-21 2008-03-27 Raqualia Pharma Inc. Composés tricycliques
WO2008050199A2 (fr) 2006-10-23 2008-05-02 Pfizer Japan Inc. Composés de phénylméthyl bicyclocarboxyamide substitués
JP4599462B2 (ja) * 2007-02-02 2010-12-15 ファイザー・プロダクツ・インク 三環式化合物およびそれらのグルココルチコイド受容体調節剤としての使用
EP2160381A2 (fr) * 2007-05-24 2010-03-10 Pfizer Limited Dérivés spirocycliques de quinazoline et leur utilisation comme inhibiteurs de pde7
CN101084891A (zh) * 2007-06-29 2007-12-12 北京本草天源药物研究院 一种用于口服的达非那新或其药用盐的药物制剂
US20090005431A1 (en) * 2007-06-30 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
US8323695B2 (en) 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
CZ300895B6 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
US20110092564A1 (en) * 2008-02-26 2011-04-21 Ernest Puil Cyclic amino acids for the treatment of pain
WO2009140078A1 (fr) * 2008-05-16 2009-11-19 The Procter & Gamble Company Traitement d’un dysfonctionnement de l’appareil urinaire bas par des agonistes sélectifs du récepteur cb‑2
US20110217387A1 (en) * 2008-05-16 2011-09-08 Axis, Inc. Pharmaceutical composition for treatment of fibromyalgia
US8435564B2 (en) * 2008-05-30 2013-05-07 Ucb Pharma, S.A. Pharmaceutical compositions comprising brivaracetam
JP5576370B2 (ja) * 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
EP2163253B1 (fr) 2008-09-15 2013-07-17 ULLRICH, Oliver Extraits de la plante Hornstedtia scyphifera et ses effets immunosuppresseurs
CN102224142B (zh) 2008-11-21 2015-07-22 拉夸里亚创药株式会社 具有5-ht2b受体拮抗活性的新型吡唑-3-羧酰胺衍生物
PT2385938E (pt) 2009-01-12 2015-06-02 Pfizer Ltd Derivados de sulfonamida
CN102369212B (zh) 2009-03-12 2015-12-16 哈瑟投资公司 具有降低的bmp拮抗剂敏感性的骨形成蛋白2(bmp2)变体
EP2233502A1 (fr) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Anticorps spécifiques à l'antigène syalilé pour le traitement ou prophylaxie des réactions immunitaires inflammatoires non désirables et leurs procédés de production
EP2236516A1 (fr) 2009-03-31 2010-10-06 Charité-Universitätsmedizin Berlin (Charité) Polypeptides et utilisation associée pour le traitement d'une lésion neuronale traumatique ou dégénérative
SG175738A1 (en) 2009-05-29 2011-12-29 Pfizer Ltd Novel glucocorticoid receptor agonists
EP2266563A1 (fr) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Utilisation d'antagonistes de récepteur opioïde pour le traitement aigu des états d'éveil paraphiliques
WO2011004276A1 (fr) 2009-07-06 2011-01-13 Pfizer Limited Inhibiteurs du virus de l’hépatite c
US8617763B2 (en) * 2009-08-12 2013-12-31 Bloom Energy Corporation Internal reforming anode for solid oxide fuel cells
US20130045948A1 (en) 2009-12-11 2013-02-21 E I Du Pont De Nemours And Company Azocyclic inhibitors of fatty acid amide hydrolase
WO2011077313A1 (fr) 2009-12-22 2011-06-30 Pfizer Inc. Pipéridinecarboxamides en tant qu'inhibiteurs de mpges - 1
SI2516434T1 (sl) 2009-12-23 2015-10-30 Takeda Pharmaceutical Company Limited Zliti heteroaromatski pirolidinoni kot inhibitorji SYK
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
EP2566858A2 (fr) 2010-05-04 2013-03-13 Pfizer Inc. Dérivés heterocycliques en tant qu'inhibiteurs d'alk
WO2011154871A1 (fr) 2010-06-10 2011-12-15 Pfizer Limited Inhibiteurs du virus de l'hépatite c
WO2011161504A1 (fr) * 2010-06-23 2011-12-29 Micro Labs Limited Formulations à libération prolongée contenant de la darifénacine ou des sels pharmaceutiquement acceptables de celle-ci
WO2012004743A1 (fr) 2010-07-09 2012-01-12 Pfizer Limited Benzènesulfonamides utiles en tant qu'inhibiteurs des canaux sodiques
CA2804173C (fr) 2010-07-09 2015-01-13 Pfizer Limited Inhibiteurs de nav1.7 de type sulfonamide
EP2590957B1 (fr) 2010-07-09 2014-11-12 Pfizer Limited N-sulfonylbenzamides comme inhibiteurs des canaux sodiques voltage-dépendant
EP2593432B1 (fr) 2010-07-12 2014-10-22 Pfizer Limited Dérivés de n-sulfonylbenzamide utiles comme inhibiteurs du canal sodique voltage-dépendant
EP2593427B1 (fr) 2010-07-12 2014-12-24 Pfizer Limited Dérivés de sulfonamides comme inhibiteurs du nav1.7 pour le traitement de la douleur
EP2593433B1 (fr) 2010-07-12 2014-11-26 Pfizer Limited N-sulfonylbenzamides comme inhibiteurs des canaux sodiques voltage-dépendan
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
WO2012007868A2 (fr) 2010-07-12 2012-01-19 Pfizer Limited Composés chimiques
WO2012042421A1 (fr) 2010-09-29 2012-04-05 Pfizer Inc. Procédé de traitement de la croissance cellulaire anormale
JP5902704B2 (ja) 2010-11-15 2016-04-13 ヴィーブ ヘルスケア ユーケー リミテッド Ｈｉｖ複製の阻害剤
EP2457900A1 (fr) 2010-11-25 2012-05-30 Almirall, S.A. Nouveaux dérivés de pyrazole présentant un comportement antagoniste CRTH2
EP2463289A1 (fr) 2010-11-26 2012-06-13 Almirall, S.A. Dérivés imidazo[1,2-b]pyridazine en tant qu'inhibiteur JAK
CN102048706B (zh) * 2011-01-12 2012-02-22 山东创新药物研发有限公司 一种氢溴酸达非那新缓释片及制备方法
WO2012095781A1 (fr) 2011-01-13 2012-07-19 Pfizer Limited Dérivés d'indazole comme inhibiteurs des canaux sodiques
EP2489663A1 (fr) 2011-02-16 2012-08-22 Almirall, S.A. Composés en tant qu'inhibiteurs de la syk kinase
AR085406A1 (es) 2011-02-25 2013-09-25 Takeda Pharmaceutical Oxazinopteridinas y oxazinopteridinonas n-sustituidas
WO2012120398A1 (fr) 2011-03-04 2012-09-13 Pfizer Limited Dérivés de carboxamide substitués par aryle en tant que modulateurs de trpm8
WO2012137089A1 (fr) 2011-04-05 2012-10-11 Pfizer Limited Dérivés de pyrrolo-[2,3-d]pyrimidine en tant qu'inhibiteurs des kinases associées à la tropomyosine
EP2518071A1 (fr) 2011-04-29 2012-10-31 Almirall, S.A. Dérivés d'imidazopyridine en tant qu'inhibiteurs PI3K
EP2518070A1 (fr) 2011-04-29 2012-10-31 Almirall, S.A. Dérivés de pyrrolotriazinon en tant qu'inhibiteurs PI3K
US20120289562A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder
CA2835277A1 (fr) 2011-05-10 2012-11-15 Theravida, Inc. Combinaisons de solifenacine et de stimulants salivaires pour le traitement d'une vessie hyperactive
KR20140041524A (ko) 2011-05-18 2014-04-04 라퀄리아 파마 인코포레이티드 4-｛[4-(｛[4-(2,2,2-트리플루오로에톡시)-1,2-벤즈이속사졸-3-일]옥시｝메틸)피페리딘-1-일]메틸｝-테트라히드로-2h-피란-4-카르복실산의 다형
EP2527344A1 (fr) 2011-05-25 2012-11-28 Almirall, S.A. Dérivés de pyridin-2(1h)-one utiles comme médicaments pour le traitement de maladies myeloproliferatives, de rejets de greffe, de maladies a médiation immune et de maladies inflammatoires
EP2526945A1 (fr) 2011-05-25 2012-11-28 Almirall, S.A. Nouveaux antagonistes de CRTH2
JP6026525B2 (ja) 2011-06-22 2016-11-16 武田薬品工業株式会社 置換６−アザ−イソインドリン−１−オン誘導体
EP2548876A1 (fr) 2011-07-18 2013-01-23 Almirall, S.A. Nouveaux antagonistes de CRTH2
EP2548863A1 (fr) 2011-07-18 2013-01-23 Almirall, S.A. Nouveaux antagonistes de CRTH2
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2554544A1 (fr) 2011-08-01 2013-02-06 Almirall, S.A. Dérivés de pyridin-2(1h)-one en tant qu'inhibiteurs de JAK
CA2842493A1 (fr) 2011-08-02 2013-02-07 James Gail Christensen Crizotinib pour l'utlisation dans le traitement de cancer
WO2013054185A1 (fr) 2011-10-13 2013-04-18 Pfizer, Inc. Dérivés de pyrimidine et de pyridine utiles en thérapie
MX2014004743A (es) 2011-10-19 2014-08-01 Zoetis Llc Uso de derivados de aminoacetonitrilo contra endoparasitos.
JP5363636B2 (ja) 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
MX337469B (es) 2011-10-26 2016-03-02 Pfizer Ltd Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio.
WO2013061297A1 (fr) 2011-10-28 2013-05-02 Pfizer Limited Dérivés de pyridazine utiles en thérapie
CA2857603C (fr) 2011-12-15 2016-08-02 Pfizer Limited Derives de sulfonamide
WO2013093688A1 (fr) 2011-12-19 2013-06-27 Pfizer Limited Dérivés sulfonamides et leur utilisation en tant qu'inhibiteurs de vgsc
CN102579379B (zh) * 2011-12-29 2016-08-10 北京科信必成医药科技发展有限公司 一种药物缓释制剂及其制备方法
CN102600096B (zh) * 2011-12-29 2016-08-10 北京科信必成医药科技发展有限公司 一种达非那新缓释制剂及其制备方法
EP2800740A1 (fr) 2012-01-04 2014-11-12 Pfizer Limited N-aminosulfonylbenzamides
CA2861439C (fr) 2012-02-03 2016-07-12 Pfizer Inc. Derives d'imidazopyridine et de benziimidazole en tant que modulateurs du canal sodium
NZ627900A (en) 2012-03-06 2016-08-26 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
US9365566B2 (en) 2012-03-27 2016-06-14 Takeda Pharmaceutical Company Limited Cinnoline derivatives
US9353062B2 (en) 2012-04-04 2016-05-31 Hangzhouderenyucheng Biotechnology Ltd Substituted quinolines as bruton's tyrosine kinases inhibitors
UY34893A (es) 2012-07-10 2014-02-28 Takeda Pharmaceutical Derivados de azaindol
WO2014039831A1 (fr) 2012-09-07 2014-03-13 Takeda Pharmaceutical Company Limited Dihydropyrazolo[4,3-b]indoles substituées dans les positions 1 et 4
EP2897950A1 (fr) 2012-09-18 2015-07-29 Ziarco Pharma Ltd 2-(2-aminocyclohexyl)aminopyrimidino-5-carboxamides utilisés comme inhibiteurs de la spleen tyrosine kinase (syk)
EP2900653A1 (fr) 2012-09-28 2015-08-05 Pfizer Inc. Composés de benzamide et hétérobenzamide
JP2015531394A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［２，３−ｄ］ピリミジントロポミオシン関連キナーゼ阻害剤
EP2912036A1 (fr) 2012-10-04 2015-09-02 Pfizer Limited Inhibiteurs de kinase associée à la tropomyosine pyrrolo[3,2-c]pyridine
US20150250785A1 (en) 2012-10-04 2015-09-10 Pfizer Limited Tropomyosin-Related Kinase Inhibitors
WO2014060431A1 (fr) 2012-10-16 2014-04-24 Almirall, S.A. Dérivés de pyrrolotriazinone en tant qu'inhibiteurs des pi3k
AU2013343104A1 (en) 2012-11-08 2015-04-23 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
JP5823657B1 (ja) 2012-11-08 2015-11-25 ファイザー・インク ドーパミンｄ１リガンドとしての複素芳香族化合物
EP2922849B1 (fr) 2012-11-21 2017-07-12 RaQualia Pharma Inc. Polymorphes du 4-{[4-({[4-(2,2,2-trifluoroéthoxy)-1,2-benzisoxazol-3-yl]oxy}méthyl)pipéridin-1-yl]méthyl}-tetrahydro-2h-pyran-4-acide carboxilique en tant qu'agonistes du recepteur 5-hydroxytryptamine-4 (5-ht4) pour le traitement de maladies gastrointestinales
CA2891234C (fr) 2012-12-03 2017-03-07 Pfizer Inc. Modulateurs de recepteur androgene selectifs
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
AR094797A1 (es) 2013-02-15 2015-08-26 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
KR101858913B1 (ko) 2013-02-21 2018-05-16 화이자 인코포레이티드 고체 형태의 선택적인 cdk4/6 억제제
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
JP2016510787A (ja) * 2013-03-13 2016-04-11 ラシオファルム ゲーエムベーハー クリゾチニブを含む剤形
EP2784083A1 (fr) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Variantes de protéine morphogénétique osseuse (BMP) avec sensibilité antagoniste fortement réduite et meilleure activité biologique spécifique
EP2792360A1 (fr) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide pour utilisation dans le traitement de HCV
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
WO2014181213A1 (fr) 2013-05-10 2014-11-13 Pfizer Inc. Forme cristalline de (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
WO2014186742A2 (fr) 2013-05-17 2014-11-20 Acupac Packaging, Inc. Composition d'hydrogel anhydre
MA38661A1 (fr) 2013-06-27 2017-03-31 Pfizer Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
EP3083602A1 (fr) 2013-12-20 2016-10-26 Pfizer Limited Inhibiteurs de kinase apparentés à la n-acylpipéridine éther tropomyosine
WO2015092614A1 (fr) 2013-12-20 2015-06-25 Pfizer Inc. Altérations d'activation de notch dans le cancer du sein
US9371321B2 (en) 2014-01-09 2016-06-21 Astrazeneca Ab Azaindole derivatives
WO2015106014A1 (fr) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Dérivés d'azaindole
WO2015159175A1 (fr) 2014-04-15 2015-10-22 Pfizer Inc. Inhibiteurs de kinases apparentées à la tropomyosine contenant à la fois un 1h-pyrazole et un fragment pyrimidine
WO2015162518A1 (fr) 2014-04-25 2015-10-29 Pfizer Inc. Composes hetero-aromatiques et leur utilisation comme ligands d1 de la dopamine
WO2015162515A1 (fr) 2014-04-25 2015-10-29 Pfizer Inc. Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1
MX2016013969A (es) 2014-04-25 2017-01-11 Pfizer Compuestos heteroaromaticos y su uso como ligandos de dopamina d1.
CA2946990A1 (fr) 2014-04-28 2015-11-05 Pfizer Inc. Composes heterocycliques et leur utilisation comme ligands des recepteurs d1 de la dopamine
WO2015166370A1 (fr) 2014-04-28 2015-11-05 Pfizer Inc. Composés hétéroaromatiques et leur utilisation en tant que ligands de la dopamine d1
EP3140298A1 (fr) 2014-05-07 2017-03-15 Pfizer Inc. Inhibiteurs de kinases apparentées à la tropomyosine
MD20160121A2 (ro) 2014-05-14 2017-05-31 Pfizer Inc. Pirazolopiridine şi pirazolopirimidine
EP3143019B1 (fr) 2014-05-15 2020-12-16 Pfizer Inc Forme cristalline du 6-[(4r)-4-méthyl -1,2-dioxydo-1,2,6-thiadiazinan -2-yle]isoquinoline-1-carbonitrile
ES2747989T3 (es) 2014-05-20 2020-03-12 Raqualia Pharma Inc Sal de derivado de benzisoxazol
RU2016146826A (ru) 2014-05-30 2018-07-04 Пфайзер Инк. Производные карбонитрилов как селективные модуляторы андрогенового рецептора
CA2950393A1 (fr) 2014-05-30 2015-12-03 Pfizer Inc. Benzenesulfonamides utiles en tant qu'inhibiteurs des canaux sodiques
US9802945B2 (en) 2014-06-12 2017-10-31 Pfizer Limited Imidazopyridazine derivatives as modulators of the GABAA receptor activity
WO2015193768A1 (fr) 2014-06-17 2015-12-23 Pfizer Inc. Lactames à fusion aryle à utiliser en tant que modulateurs ezh2
PT3157915T (pt) 2014-06-17 2019-05-16 Pfizer Compostos de dihidroisoquinolinona substituídos
WO2016009296A1 (fr) 2014-07-16 2016-01-21 Pfizer Inc. Inhibiteurs de kinase liés à la n-acylpipéridine éther tropomyosine
WO2016009303A1 (fr) 2014-07-17 2016-01-21 Pfizer Inc. Associations de produits pharmaceutiques comprenant de la gabapentine ou de la prégabaline avec des inhibiteurs de nav1.7
WO2016009297A1 (fr) 2014-07-18 2016-01-21 Pfizer Inc. Dérivés de la pyridine en tant que modulateurs allostériques positifs du récepteur m1 muscarinique
WO2016020784A1 (fr) 2014-08-05 2016-02-11 Pfizer Inc. Inhibiteurs de kinases apparentées à la n-acylpyrrolidine éther tropomyosine
WO2016034971A1 (fr) 2014-09-04 2016-03-10 Pfizer Limited Dérivés sulfonamides utilisés en tant qu'inhibiteurs d'urat1
US10017529B2 (en) 2014-09-16 2018-07-10 BioPharma Works LLC Metformin derivatives
GB201417163D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
WO2016067143A1 (fr) 2014-10-28 2016-05-06 Pfizer Inc. Composés n- (2-alkylèneimino-3-phénylpropyl)acétamide et leur utilisation contre la douleur et le prurit par inhibition des canaux trpa1
EP3233829B1 (fr) 2014-12-18 2019-08-14 Pfizer Inc Dérivés de pyrimidine et de triazine, et leur utilisation comme inhibiteurs d'axl
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
US9765000B2 (en) 2015-01-22 2017-09-19 Phytoplant Research S.L. Methods of purifying cannabinoids, compositions and kits thereof
JP6584521B2 (ja) 2015-02-24 2019-10-02 ファイザー・インク 抗がん剤として有用な置換ヌクレオシド誘導体
CN107847609A (zh) 2015-03-13 2018-03-27 恩多塞特公司 用于治疗疾病的缀合物
WO2016170009A1 (fr) 2015-04-21 2016-10-27 Almirall, S.A. Dérivés hétérocycliques amino-substitués utilisés comme inhibiteurs des canaux sodiques
EP3636283A1 (fr) 2015-06-04 2020-04-15 Pfizer Inc Formes galéniques solides de palbociclib
MX2018000929A (es) 2015-07-31 2018-05-22 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl.
WO2017060488A1 (fr) 2015-10-09 2017-04-13 Almirall, S.A. Nouveaux antagonistes de trpa1
WO2017064068A1 (fr) 2015-10-14 2017-04-20 Almirall, S.A. Nouveaux antagonistes de trpa1
EP3386983A1 (fr) 2015-12-10 2018-10-17 Pfizer Limited Dérivés 4-(biphényl-3-yl)-1h-pyrazolo[3,4-c]pyridazine de formule (i) utilisés comme modulateurs de récepteur gaba pour le traitement de l'épilepsie et de la douleur
JP6876704B2 (ja) 2015-12-24 2021-05-26 武田薬品工業株式会社 共結晶、その製造方法、及び共結晶を含有する医薬
JP2019501222A (ja) 2016-01-07 2019-01-17 シーエス ファーマテック リミテッド Ｅｇｆｒチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬
WO2017119732A1 (fr) 2016-01-08 2017-07-13 Samsung Electronics Co., Ltd. Dispositif électronique, et son procédé de fonctionnement
CN108884093B (zh) 2016-01-15 2021-07-09 辉瑞公司 一种多巴胺d3配体化合物
EP3405191A4 (fr) 2016-01-20 2019-09-04 TheraVida, Inc. Méthodes et compositions pour le traitement de l'hyperhidrose
CN108884445A (zh) 2016-03-09 2018-11-23 北京智康博药肿瘤医学研究有限公司 肿瘤细胞悬浮培养物和相关方法
US20190105407A1 (en) 2016-03-31 2019-04-11 Takeda Pharmaceutical Company Limited Isoquinolinyl triazolone complexes
CA2969295A1 (fr) 2016-06-06 2017-12-06 Pfizer Inc. Derives de carbonucleosides substitues et leur utilisation comme inhibiteur de prmt5
AU2017310526B2 (en) 2016-08-12 2021-08-12 Edwin J. Iwanowicz Protein kinase regulators
UA124804C2 (uk) 2016-08-15 2021-11-24 Пфайзер Інк. Піридопіримідинонові інгібітори cdk2/4/6
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
JP7273723B2 (ja) 2016-12-20 2023-05-15 オリゴメリックス インコーポレイテッド タウオリゴマーの形成を阻害する新規キナゾリノン及びその使用方法
CN110382479A (zh) 2017-01-20 2019-10-25 辉瑞大药厂 作为magl抑制剂的氨基甲酸1,1,1-三氟-3-羟基丙-2-基酯衍生物
EP3571202B1 (fr) 2017-01-23 2021-06-30 Pfizer Inc. Composés spiro hétérocycliques utilisés en tant qu'inhibiteurs de magl
CA3051038C (fr) 2017-01-24 2022-07-26 Pfizer Inc. Derives de calicheamicine et conjugues anticorps-medicaments de ceux-ci
JP7142675B2 (ja) 2017-03-26 2022-09-27 武田薬品工業株式会社 Ｇｐｒ６のモジュレーターとしてのピペリジニルおよびピペラジニル置換された複素芳香族カルボキサミド
JOP20180057A1 (ar) 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
JP7296954B2 (ja) 2017-06-22 2023-06-23 キュラデブ・ファーマ・リミテッド ヒトｓｔｉｎｇの小分子調節因子
RU2020112502A (ru) 2017-08-30 2021-10-01 Бейцзин Сюаньи Фармасайенсиз Ко., Лтд. Циклические динуклеотиды в качестве стимулятора модуляторов генов интерферона
WO2019051469A1 (fr) 2017-09-11 2019-03-14 Krouzon Pharmaceuticals, Inc. Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2
TW201920108A (zh) 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
AU2018369841A1 (en) 2017-11-14 2020-05-07 Pfizer Inc. EZH2 inhibitor combination therapies
AU2019211188A1 (en) 2018-01-29 2020-07-30 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
EP3758753A1 (fr) 2018-02-27 2021-01-06 Pfizer Inc Association d'un inhibiteur de kinases dépendantes des cyclines et d'un inhibiteur de bromodomaines bet
WO2019169153A1 (fr) 2018-03-01 2019-09-06 Takeda Pharmaceutical Company Limited Pipéridinyl-3-(aryloxy)propanamides et propanoates
MA52360A (fr) 2018-04-26 2021-03-03 Pfizer Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines
WO2019243823A1 (fr) 2018-06-21 2019-12-26 Curadev Pharma Limited Modulateurs azahétérocycliques à petites molécules de sting humain
US20210309669A1 (en) 2018-07-19 2021-10-07 Pfizer Inc. Heterocyclic Spiro Compounds As MAGL Inhibitors
WO2020076728A1 (fr) 2018-10-08 2020-04-16 Takeda Pharmaceutical Company Limited Oxazinoptéridinones substituées en tant qu'inhibiteurs de mtor
US11142525B2 (en) 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
CA3127290A1 (fr) 2019-01-23 2020-07-30 Pfizer Inc. Forme polymorphe d'un sel d'hydrate de monophosphate d'un derive de tetrahydroisoquinoline connu
MX2021009276A (es) 2019-01-31 2021-08-24 Pfizer Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidora sobre cdk2.
US20220125777A1 (en) 2019-02-01 2022-04-28 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
CN113795251A (zh) 2019-02-27 2021-12-14 马德拉治疗公司 酪蛋白水解蛋白酶p功能作为药物对imipridone样试剂响应的生物标志物的用途
TW202102498A (zh) 2019-03-22 2021-01-16 日商武田藥品工業股份有限公司 作為ripk2 抑制劑之吡啶稠合咪唑及吡咯衍生物
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
BR112021021508A2 (pt) 2019-04-29 2022-03-22 Solent Therapeutics Llc Derivados de 3-amino-4h-benzo[e][1,2,4]tiadiazina 1,1-dióxido como inibidores de mrgx2
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
CA3147407A1 (fr) 2019-07-25 2021-01-28 Curadev Pharma Pvt. Ltd. Inhibiteurs a petites molecules de l'acetyl-coenzyme a synthetase a chaine courte 2 (acss2)
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
MX2022003177A (es) 2019-09-16 2022-04-06 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol.
IL295388A (en) 2020-02-12 2022-10-01 Curadev Pharma Pvt Ltd Sting antagonists are small molecules
WO2021176349A1 (fr) 2020-03-05 2021-09-10 Pfizer Inc. Combinaison d'un inhibiteur de kinase du lymphome anaplasique et d'un inhibiteur de kinase dépendant de la cycline
AR121683A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
AR121682A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
CA3171349A1 (fr) 2020-04-08 2021-10-14 Mission Therapeutics Limited N-cyanopyrrolidines ayant une activite en tant qu'inhibiteurs de l'usp30
PE20230323A1 (es) 2020-05-01 2023-02-22 Pfizer Compuestos de azalactama como inhibidores de hpk1
KR20230005893A (ko) 2020-05-04 2023-01-10 다케다 야쿠힌 고교 가부시키가이샤 내강 작용 n-(피페리딘-4-일)벤즈아미드 유도체
WO2021224818A1 (fr) 2020-05-08 2021-11-11 Pfizer Inc. Composés d'isoindolone en tant qu'inhibiteurs de hpk1
KR20230016674A (ko) 2020-05-28 2023-02-02 미션 테라퓨틱스 엘티디 미토콘드리아 기능장애의 치료를 위한 usp30 억제제로서 n-(1-시아노피롤리딘-3-일)-5-(3-(트라이플루오로메틸)페닐)옥사졸-2-카복스아미드 유도체 및 상응하는 옥사다이아졸 유도체
BR112022019722A2 (pt) 2020-06-04 2022-12-20 Mission Therapeutics Ltd N-cianopirrolidinas com atividade como inibidores de usp30
JP2023528087A (ja) 2020-06-08 2023-07-03 ミッション セラピューティクス リミティド ミトコンドリア機能不全、癌、及び線維症の治療に使用されるＵＳＰ３０阻害剤としての１－（５－（２－シアノピリジン－４－イル）オキサゾール－２－カルボニル）－４－メチルヘキサヒドロピロロ［３，４－ｂ］ピロール－５（１Ｈ）－カルボニトリル
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
US20240116937A1 (en) 2020-07-15 2024-04-11 Pfizer Inc. Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
WO2022013692A1 (fr) 2020-07-15 2022-01-20 Pfizer Inc. Polymorphes de (1s,2s,3s,5r)-3-((6-(difluorométhyl)-3-((6-(difluorométhyl)-5-fluoro-1,2,3,4-tétrahydroisoquinolin-8-yl)oxy)-5-(4-méthyl-7h-pyrrolo[2,3-d]pyrimidin-7-yl) cyclopentane-1,2-diol monochlorhydrate
CA3189632A1 (fr) 2020-07-20 2022-01-27 Pfizer Inc. Polytherapie
WO2022018667A1 (fr) 2020-07-24 2022-01-27 Pfizer Inc. Polythérapies utilisant des inhibiteurs de cdk2 et de cdc25a
GB202011811D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
GB202011812D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
JP2023537595A (ja) 2020-08-13 2023-09-04 ファイザー・インク 併用治療
CA3195063A1 (fr) 2020-09-15 2022-03-24 Pfizer Inc. Formes solides d'un inhibiteur de cdk4
TW202229239A (zh) 2020-09-23 2022-08-01 日商武田藥品工業股份有限公司 作為ｒｉｐｋ２抑制劑之３－（６－胺基吡啶－３－基）苯甲醯胺衍生物
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
WO2022137174A1 (fr) 2020-12-22 2022-06-30 Pfizer Inc. Formes solides d'un inhibiteur de eif4e
KR20230122100A (ko) 2020-12-24 2023-08-22 화이자 인코포레이티드 Cdk2 억제제의 고체 형태
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
KR20230159510A (ko) 2021-03-24 2023-11-21 화이자 인코포레이티드 Ddr 유전자 돌연변이된 전이성 거세-감수성 전립선암의 치료를 위한 탈라조파립과 항안드로겐의 조합
GB202104609D0 (en) 2021-03-31 2021-05-12 Sevenless Therapeutics Ltd New Treatments for Pain
EP4313151A1 (fr) 2021-03-31 2024-02-07 Sevenless Therapeutics Limited Inhibiteurs de sos1 et inhibiteurs de ras destinés à être utilisés dans le traitement de la douleur
WO2022214869A2 (fr) 2021-04-07 2022-10-13 Lifearc Inhibiteurs ulk1/2 et leur utilisation
WO2022229846A1 (fr) 2021-04-29 2022-11-03 Pfizer Inc. Traitement du cancer à l'aide d'un inhibiteur du récepteur du facteur de croissance transformant bêta de type 1
EP4359082A1 (fr) 2021-06-26 2024-05-01 Array BioPharma Inc. Inhibiteurs de mutation her2
WO2023002362A1 (fr) 2021-07-22 2023-01-26 Pfizer Inc. Traitement d'une malignité hématologique
KR20240046742A (ko) 2021-08-11 2024-04-09 큐라데브 파마 프라이버트 리미티드 소분자 sting 길항제
IL310679A (en) 2021-08-11 2024-04-01 Curadev Pharma Pvt Ltd Urea history of small molecules as STING antagonists
WO2023084459A1 (fr) 2021-11-15 2023-05-19 Pfizer Inc. Méthodes de traitement du sars-cov-2
WO2023099072A1 (fr) 2021-12-01 2023-06-08 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Composés
WO2023099561A1 (fr) 2021-12-01 2023-06-08 Mission Therapeutics Limited N-cyanopyrrolidines substituées ayant une activité en tant qu'inhibiteurs de l'usp30
WO2023100134A1 (fr) 2021-12-02 2023-06-08 Pfizer Inc. Méthodes et schémas posologiques comprenant un inhibiteur de cdk2 et un inhibiteur de cdk4 pour le traitement du cancer
WO2023187677A1 (fr) 2022-03-30 2023-10-05 Takeda Pharmaceutical Company Limited Dérivés de n-(pyrrolidin-3-yl or pipéridin-4-yl)acétamide
WO2023194964A1 (fr) 2022-04-07 2023-10-12 Takeda Pharmaceutical Company Limited Dérivés de pyridazine fusionnés utilisés comme inhibiteurs de nlrp3
WO2024013567A1 (fr) 2022-07-15 2024-01-18 Jazz Pharmaceuticals Ireland Limited Composés de biaryl-éther-urée utiles comme inhibiteurs de la faah
US20240109915A1 (en) 2022-07-29 2024-04-04 Pfizer Inc. Novel acc inhibitors
WO2024033845A1 (fr) 2022-08-10 2024-02-15 Takeda Pharmaceutical Company Limited Composé hétérocyclique
WO2024033513A1 (fr) 2022-08-11 2024-02-15 Diaccurate Composés pour le traitement du cancer
WO2024074827A1 (fr) 2022-10-05 2024-04-11 Sevenless Therapeutics Limited Nouveaux traitements de la douleur

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
PT93637A (pt) * 1989-04-20 1990-11-20 Procter & Gamble Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness

Also Published As

Publication number Publication date
NL300190I1 (nl) 2005-07-01
HUP9802339A2 (hu) 1999-08-30
CN1303998C (zh) 2007-03-14
DK1245231T3 (da) 2004-10-25
CY2585B2 (en) 2009-11-04
DE69626397T2 (de) 2003-07-17
HU225236B1 (en) 2006-08-28
DE122005000024I1 (de) 2005-08-04
TW442300B (en) 2001-06-23
AU703866B2 (en) 1999-04-01
DE69632753D1 (de) 2004-07-22
AR005231A1 (es) 1999-04-28
CO4750822A1 (es) 1999-03-31
ATE269076T1 (de) 2004-07-15
BR122012014331B1 (pt) 2019-10-08
BR9610153A (pt) 1999-01-05
BR122012014331A2 (fr) 1999-01-05
ZA967745B (en) 1998-03-13
DE69626397D1 (de) 2003-04-03
CN1195984A (zh) 1998-10-14
HUP9802339A3 (en) 1999-09-28
DK0850059T3 (da) 2003-03-31
NO981073L (no) 1998-03-11
WO1997009980A1 (fr) 1997-03-20
PL185604B1 (pl) 2003-06-30
NO2005009I2 (no) 2006-11-27
FR05C0019I2 (fr) 2005-11-04
HU227397B1 (en) 2011-05-30
DE69632753T2 (de) 2005-07-14
US6106864A (en) 2000-08-22
CA2230314C (fr) 2003-06-24
NZ316924A (en) 1999-06-29
NO981073D0 (no) 1998-03-11
PL325598A1 (en) 1998-08-03
GB9518953D0 (en) 1995-11-15
JP3403203B2 (ja) 2003-05-06
NO314783B1 (no) 2003-05-26
EP1245231B1 (fr) 2004-06-16
ATE233090T1 (de) 2003-03-15
DE122005000024I2 (de) 2006-11-23
ES2188782T3 (es) 2003-07-01
CY2005007I1 (el) 2009-11-04
TR199800461T1 (xx) 1998-05-21
RU2163803C2 (ru) 2001-03-10
CZ73298A3 (cs) 1999-03-17
EP1245231A3 (fr) 2003-01-15
KR19990044653A (ko) 1999-06-25
BR122012014331A8 (pt) 2018-07-31
EP0850059A1 (fr) 1998-07-01
MY125662A (en) 2006-08-30
CY2005007I2 (el) 2009-11-04
HU0500976D0 (en) 2005-12-28
BR122012014331B8 (pt) 2021-05-25
ES2224002T3 (es) 2005-03-01
CA2230314A1 (fr) 1997-03-20
IL122746A (en) 2000-12-06
NO2005009I1 (no) 2005-04-18
CZ294024B6 (cs) 2004-09-15
JPH10511112A (ja) 1998-10-27
EP1245231A2 (fr) 2002-10-02
EG23826A (en) 2007-09-25
KR100348585B1 (ko) 2002-10-31
AU6927596A (en) 1997-04-01
PT1245231E (pt) 2004-10-29
NL300190I2 (nl) 2005-08-01
EP0850059B1 (fr) 2003-02-26
MX9802026A (es) 1998-08-30
IL122746A0 (en) 1998-08-16
CY2468B1 (en) 2005-06-03
FR05C0019I1 (fr) 2005-05-27

Similar Documents

Publication Publication Date Title
LU91163I2 (fr) Hydrobromure de darifénacine et ses dérivés pharmaceutiquement acceptables (EMSELEX.
LU91673I2 (fr) "Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)"
LU91122I2 (fr) Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva).
LU91655I2 (fr) Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®)
LU90736I2 (fr) Agenerase-amprenavir et ses d-riv-s pharmaceutiquement acceptables
LU91205I2 (fr) Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)
LU91076I2 (fr) Tulathromycin et ses sels pharmaceutiquement acceptables (draxxin).
LU91138I2 (fr) Glulisine d'insuline et ses dérivés pharmaceutiquement acceptables.
LU91189I2 (fr) Atazanavir sulphate et ses dérivés pharmaceutiquement acceptables (REYATAZ)
LU91298I2 (fr) Pioglitazone en association avec la metformine et ses dérivés pharmaceutiquement acceptables-competact
LU91269I2 (fr) Rotigotine et ses dérivés pharmaceutiquement acceptables (neupro)
HUP9801910A3 (en) Dolastatin derivatives, their preparation and use
PT853617E (pt) Novos derivados de 2,3-dioxo-1,2,3,4-tetrahidro-quinoxalinilo
TR199600471A2 (tr) COCCIDIOSIS'e karsi uygulanan yumurta ici asilama.
ES1034944Y (es) "distribuidor de tabletas."
HUP9901990A3 (en) Furan- and thiophene derivatives having inhibitor effect on the replication of hiv-1 and hiv-1 mutants, and medicaments containing the same
LU90110I2 (fr) Penciclovir et ses dérivés pharmaceutiquement acceptables
DE69636837D1 (de) 1,2,4-benzotriazinoxid-formulierungen
FR2735776B1 (fr) Derives de 2,3-dihydro-1h-indole, leur preparation et leur application en therapeutique
DE29506326U1 (de) Kondom
BR9605220A (pt) Gonadotropinas e composiçao farmacêutica
BR9508669A (pt) Novos derivados de taizoloÚ3,2-a¾quinolina e naftirina
LU88789I2 (fr) Mésylate de tirilazad et ses dérivés pharmaceutiquement acceptables (Freedox (R))
DE29506898U1 (de) Serviettenring
KR960030461U (ko) 음경용 링